US FDA approves new class of HIV therapeutics.
Debra
D
Robertson
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D019380:Anti-HIV Agents / Q000145:classification / Q000191:economics / Q000627:therapeutic use; D000998:Antiviral Agents / Q000145:classification* / Q000191:economics / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000145:classification / Q000191:economics / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000145:classification / Q000191:economics / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D010446:Peptide Fragments / Q000145:classification / Q000191:economics / Q000627:therapeutic use*; D014481:United States
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide